Reuters: Regulatory News: UPDATE 1-MannKind licenses cancer compound to Tolero

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-MannKind licenses cancer compound to Tolero Apr 30th 2012, 10:31 April 30 | Mon Apr 30, 2012 6:31am EDT April 30 (Reuters) - MannKind Corp licensed worldwide rights of its compounds to treat cancer and inflammatory diseases to privately held Tolero Pharmaceuticals. The total potential upfront and milestone payments to MannKind could reach $130 million, the companies said in a joint statement. MannKind is currently testing its compounds for the treatment of cancers of the blood, bone marrow, and lymph nodes and inflammatory diseases. Shares of the company closed at $2.24 on Friday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions